Sign in
PTN Stock Price, Chart, Stats & News
Palatin Technologies, Inc.
Save
Palatin Technologies, Inc. (PTN) does not currently pay a dividend.
–
Market cap
94.00x
Current P/E
42.92x
Forward P/E
PTN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.25% |
Operating margin | -134.80% |
Pretax margin | -107.41% |
Net margin | -107.41% |
Effective tax rate | – |
ROA | -53.70% |
ROE | -5515.09% |
D/E | 0.03x |
Interest coverage ratio | -1552.93x |
PTN valuation
P/E | 94.00x |
P/S | 58.00x |
P/B | 1.69x |
P/CF | -1.22x |
P/FCF | -32.73x |
P/OCF | -1.22x |
PEG | 0.01x |
EV multiple | -55.83x |
About
Palatin Technologies, Inc. is a biopharmaceutical firm specializing in the creation of precise, receptor-targeting treatments for various medical conditions throughout the United States. Its flagship product is Vyleesi, a melanocortin receptor (MCr) agonist prescribed for premenopausal women experiencing hypoactive sexual desire disorder. The company's pipeline also includes oral PL8177, a selective MC1r agonist peptide that has successfully concluded Phase I clinical trials for inflammatory bowel diseases.
Similar securities
Based on sector and market capitalization
Report issue